131 related articles for article (PubMed ID: 7596218)
1. Effects of an aldose reductase inhibitor on erythrocyte fructose 3-phosphate and sorbitol 3-phosphate levels in diabetic patients.
Hamada Y; Odagaki Y; Sakakibara F; Naruse K; Koh N; Hotta N
Life Sci; 1995; 57(1):23-9. PubMed ID: 7596218
[TBL] [Abstract][Full Text] [Related]
2. Epalrestat, an aldose reductase ihibitor, reduces the levels of Nepsilon-(carboxymethyl)lysine protein adducts and their precursors in erythrocytes from diabetic patients.
Hamada Y; Nakamura J; Naruse K; Komori T; Kato K; Kasuya Y; Nagai R; Horiuchi S; Hotta N
Diabetes Care; 2000 Oct; 23(10):1539-44. PubMed ID: 11023149
[TBL] [Abstract][Full Text] [Related]
3. Role of polyol pathway in nonenzymatic glycation.
Hamada Y; Araki N; Horiuchi S; Hotta N
Nephrol Dial Transplant; 1996; 11 Suppl 5():95-8. PubMed ID: 9044317
[TBL] [Abstract][Full Text] [Related]
4. Effects of fructose ingestion on sorbitol and fructose 3-phosphate contents of erythrocytes from healthy men.
Kawaguchi M; Fujii T; Kamiya Y; Ito J; Okada M; Sakuma N; Fujinami T
Acta Diabetol; 1996 Jul; 33(2):100-2. PubMed ID: 8870809
[TBL] [Abstract][Full Text] [Related]
5. The aldose reductase inhibitor epalrestat exerts nephritic protection on diabetic nephropathy in db/db mice through metabolic modulation.
He J; Gao HX; Yang N; Zhu XD; Sun RB; Xie Y; Zeng CH; Zhang JW; Wang JK; Ding F; Aa JY; Wang GJ
Acta Pharmacol Sin; 2019 Jan; 40(1):86-97. PubMed ID: 29930278
[TBL] [Abstract][Full Text] [Related]
6. Erythrocyte sorbitol level as a predictor of the efficacy of epalrestat treatment for diabetic peripheral polyneuropathy.
Ando H; Takamura T; Nagai Y; Kaneko S;
J Diabetes Complications; 2006; 20(6):367-70. PubMed ID: 17070440
[TBL] [Abstract][Full Text] [Related]
7. Changes in erythrocyte sorbitol concentrations measured using an improved assay system in patients with diabetic complications and treated with aldose reductase inhibitor.
Hayashi R; Hayakawa N; Makino M; Nagata M; Kakizawa H; Uchimura K; Hamada M; Aono T; Fujita T; Shinohara R; Nagasaka A; Itoh M
Diabetes Care; 1998 Apr; 21(4):672-3. PubMed ID: 9571366
[No Abstract] [Full Text] [Related]
8. Fidarestat (SNK-860), a potent aldose reductase inhibitor, normalizes the elevated sorbitol accumulation in erythrocytes of diabetic patients.
Asano T; Saito Y; Kawakami M; Yamada N;
J Diabetes Complications; 2002; 16(2):133-8. PubMed ID: 12039395
[TBL] [Abstract][Full Text] [Related]
9. Aldose reductase inhibitor, epalrestat, reduces lipid hydroperoxides in type 2 diabetes.
Ohmura C; Watada H; Azuma K; Shimizu T; Kanazawa A; Ikeda F; Yoshihara T; Fujitani Y; Hirose T; Tanaka Y; Kawamori R
Endocr J; 2009; 56(1):149-56. PubMed ID: 18997444
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological properties of fidarestat, a potent aldose reductase inhibitor, clarified by using sorbitol in human and rat erythrocytes.
Sobajima H; Aoki T; Sassa H; Suzuki T; Taniko K; Makino M; Mizuno K; Suzuki T
Pharmacology; 2001 May; 62(4):193-9. PubMed ID: 11359994
[TBL] [Abstract][Full Text] [Related]
11. In vitro retinal and erythrocyte polyol pathway regulation by hormones and an aldose reductase inhibitor.
Hotta N; Kakuta H; Koh N; Fukasawa H; Yasuma T; Awaya S; Sakamoto N
Diabetes Res Clin Pract; 1991 Oct; 14(1):29-35. PubMed ID: 1748061
[TBL] [Abstract][Full Text] [Related]
12. Effects of aldose reductase inhibitor (ONO-2235) on human erythrocyte sorbitol concentrations in 75 g oral glucose tolerance tests.
Kamon N; Mabuchi H; Takeda R; Terashima H
Horm Metab Res; 1991 May; 23(5):226-9. PubMed ID: 1908433
[TBL] [Abstract][Full Text] [Related]
13. Long-term effect of epalrestat, an aldose reductase inhibitor, on the development of incipient diabetic nephropathy in Type 2 diabetic patients.
Iso K; Tada H; Kuboki K; Inokuchi T
J Diabetes Complications; 2001; 15(5):241-4. PubMed ID: 11522497
[TBL] [Abstract][Full Text] [Related]
14. Alteration of urinary sorbitol excretion in WBN-kob diabetic rats - treatment with an aldose reductase inhibitor.
Tsugawa T; Shinohara R; Nagasaka A; Nakano I; Takeda F; Nagata M; Oda N; Sawai Y; Hayakawa N; Suzuki A; Itoh M
J Endocrinol; 2004 Jun; 181(3):429-35. PubMed ID: 15171691
[TBL] [Abstract][Full Text] [Related]
15. Effect of aldose reductase inhibitor on the inhibition of platelet aggregation induced by diabetic rat plasma.
Takiguchi Y; Wada K; Nakashima M
Eur J Pharmacol; 1992 May; 215(2-3):289-91. PubMed ID: 1396993
[TBL] [Abstract][Full Text] [Related]
16. Identification of sorbitol 3-phosphate and fructose 3-phosphate in normal and diabetic human erythrocytes.
Petersen A; Szwergold BS; Kappler F; Weingarten M; Brown TR
J Biol Chem; 1990 Oct; 265(29):17424-7. PubMed ID: 2211634
[TBL] [Abstract][Full Text] [Related]
17. Effect of an aldose reductase inhibitor on glomerular basement membrane anionic sites in streptozotocin-induced diabetic rats.
Isogai S; Inokuchi T; Ohe K
Diabetes Res Clin Pract; 1995 Nov; 30(2):111-6. PubMed ID: 8833631
[TBL] [Abstract][Full Text] [Related]
18. Effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy in patients with type 2 diabetes, in relation to suppression of N(ɛ)-carboxymethyl lysine.
Kawai T; Takei I; Tokui M; Funae O; Miyamoto K; Tabata M; Hirata T; Saruta T; Shimada A; Itoh H
J Diabetes Complications; 2010; 24(6):424-32. PubMed ID: 19716319
[TBL] [Abstract][Full Text] [Related]
19. Epalrestat, an aldose reductase inhibitor, improves an impaired generation of oxygen-derived free radicals by neutrophils from poorly controlled NIDDM patients.
Sato N; Kashima K; Uehara Y; Ohtani K; Shimizu H; Mori M
Diabetes Care; 1997 Jun; 20(6):995-8. PubMed ID: 9167113
[TBL] [Abstract][Full Text] [Related]
20. Influence of interindividual variability of aldose reductase protein content on polyol-pathway metabolites and redox state in erythrocytes in diabetic patients.
Hamada Y; Nishimura C; Koh N; Sakakibara F; Nakamura J; Tanimoto T; Hotta N
Diabetes Care; 1998 Jun; 21(6):1014-8. PubMed ID: 9614624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
